
GLP-1s and Breast Cancer – Recent Findings Suggest a Reduction in Risk, but Caution is Warranted in Interpreting the Data
By Helana Shumway, Public Relations Coordinator
The Breast Cancer Coalition does not recommend or provide medical advice. Individuals should consult with their medical or oncology teams with any questions related to their health care.

Recent headlines announced that studies have found that GLP-1s – the increasingly common weight loss drug prescribed to those who are living with diabetes or are overweight – are linked to a reduction in breast cancer incidence or potential recurrence reduction. While this news may seem groundbreaking, many experts are recommending caution until there is significant scientific evidence.
Dr. Alissa Huston is a triple-board certified physician at the Pluta Cancer Center and Wilmot Cancer Center through the University of Rochester Medical Center. “The early evidence surrounding GLP-1 medications and breast cancer is intriguing in that they not only appear safe for use in those with a history of breast cancer, but they may also provide protective benefits particularly given the relationship between obesity, metabolic health, and breast cancer outcomes,” Huston said.
“However, we are still in the early stages of understanding what these medications may mean for someone who has already been diagnosed with breast cancer and need formal, prospective research specifically in breast cancer populations to determine their role in cancer prevention, recurrence reduction, or survivorship care.”

A Review of the Study
The headlines surrounding the connection between GLP-1s and breast cancer are based on a few studies. One is from Penn Medicine, where researchers performed a retrospective analysis of over 110,000 women who were between 45 and 80 years old.(1) A retrospective analysis means that the study was observational and used existing data to analyze findings.
The analysis showed that women from the cohort who took a GLP-1 had a roughly 30% less chance of developing breast cancer compared to women who did not take the drug. While this finding seems highly significant, the 30% reduction is what is known as a relative risk reduction as opposed to an absolute risk reduction, wrote Gary Schwitzer, a renowned health care journalist with more than 50 years of experience reviewing health news, in his article “What you should know about claims that GLP-1 drugs cut breast cancer risk by 30%.”(2)
To further explain this concept: Penn’s study found that 2.3% of women not taking a GLP-1 were diagnosed with breast cancer, whereas 1.6% of women taking a GLP-1 were diagnosed with breast cancer. This results in less than a one percentage point difference, but a 30% relative difference when comparing 1.6 to 2.3%.
Both data are considered accurate, wrote Schwitzer, but regarding the number of women who developed breast cancer versus those who did not based on taking a GLP-1 or not, there was less than one percentage point difference.

An additional caveat of this observational study is that other variables were not accounted for, such as the type of GLP-1 prescribed, the length a woman was on the drug, breast cancer type and stage, and genetic predispositions. Not accounting for such variables could impact the resulting data. Penn Medicine reported plans to continue this research with a multi-site clinical trial.
Other researchers have been examining the use of GLP-1s as it relates to breast cancer survival and rates of recurrence, but these are also early-stage studies and indicate the need for further investigation.(3,4)
Key Takeaways
GLP-1s have been proven to help individuals lose weight and reduce blood sugar levels in the body.5 Being overweight is a known risk factor associated with breast cancer,4 and some experts believe that the potential benefits associated with breast cancer risk from taking a GLP-1 may be due to the overall improvements in metabolic health.(3)
Importantly, being overweight is only one of many risk factors associated with breast cancer. Conversations surrounding the use of GLP-1s – whether an individual is a breast cancer survivor or not – should be done in consultation with a medical professional.
To summarize, while headlines have reported findings regarding the connection between GLP-1s and breast cancer, it is too early to prove a causal relationship based off retrospective analyses. Further randomized trials are needed to examine if the use of GLP-1s statistically and significantly reduces the risk of breast cancer incidence or recurrence.

References:
- https://www.pennmedicine.org/news/glp-1-use-linked-to-lower-breast-cancer-incidence
- https://garyschwitzer.substack.com/p/glp-1-drugs-cut-breast-cancer-risk
- https://www.healthcentral.com/condition/breast-cancer/glp-1-drugs-and-breast-cancer
- https://www.bcrf.org/blog/what-you-need-to-know-about-glp-1s-and-breast-cancer-care/
- https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
This article first appeared in the Autumn 2026 edition of “Voices of the Ribbon.”
